Fangda assists Brattea in completing its high-value series-D financing_News_About

Fangda assists Brattea in completing its high-value series-D financing

2024 / 04 / 24

Fangda represented Shanghai Brattea Medical Technology Co., Ltd. (“Brattea”) in its series D investment. The transaction was closed in March 2024. Fangda team on this deal was led by partner Luo Ke, and the team members included Elaine Li and Joshua Tsui. Fangda assisted in the drafting and negotiation of transaction documents and the closing process. Brattea mainly engages in the R&D of medical devices in relation to nerve radiofrequency ablation, including Renal denervation (RDN) for hypertension.

Previous：Fangda represents Mindray in its strategic acquisition of the controlling shareholding right of APT, a listed company on the STAR Market Board

Next：Fangda assisted Voneseals in completing a material asset restructuring transaction through equity acquisition of Shanghai Garnor

2026 / 07 / 09

Fangda Assists Biren Technology on its HKD7 Billion H-share Placement

2026 / 07 / 07

“The first physical AI stock” — Fangda Advises Momenta on its successful Hong Kong listing

2026 / 07 / 06

Fangda Advised BlueFive and Primavera Capital on Equity Investment in Kling AI

2026 / 07 / 02

Fangda advises Junshi Biosciences on its R&D and commercialization collaboration with Fosun Wanbang for Roconkibart (IL-17A)

2026 / 06 / 24

Fangda Advises SEER TECH on Its Hong Kong 18C Listing as the “First Robot Brain Stock”